FDA grants fast track designation to gamma-delta T-cell therapy for advanced lymphoma
ADI-001 (Adicet Bio) is an allogeneic gamma-delta T-cell therapy derived from donor cells that is genetically engineered to express a CD20-directed chimeric antigen receptor. The FDA's fast track designation helps to expedite development, review and potential approval of treatments for serious or life-threatening diseases.
“Fast track designation represents an important milestone in the clinical development of ADI-001,” Chen Schor, president and CEO of Adicet Bio, said in a company-issued press release.
“We believe ADI-001 is unique in that it is designed to target malignant B cells by leveraging the innate and adaptive receptors found naturally on gamma-delta T cells with the added benefit of an engineered anti-CD20 CAR,” he added.
ارسال به دوستان